Cocrystal Pharma appoints James Sapirstein as CEO, replacing co-CEOs Lee and Martin

Cocrystal Pharma, Inc.

James Sapirstein appointed CEO effective June 3, 2026; prior CEO of Entero Therapeutics (Nasdaq: ENTO).
Sam Lee remains President and Chief Scientific Officer; James Martin remains CFO.
Sapirstein receives $265,000 base salary, 50% target bonus, and initial option grant of 235,000 shares at $1.05 vesting over 4 years.
Additional 235,000 options may be granted on 6-month anniversary subject to performance and board approval.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

James Martin

Co-Chief Executive Officer

COCP · Cocrystal Pharma, Inc.

Effective: 2026-06-03
Successor: James Sapirstein
Filed: June 9, 2026, 7:00 AM ET

Mr. Sapirstein replaces Sam Lee and James Martin, who served as the Company’s Co-Chief Executive Officers.

Departed

Sam Lee

Co-Chief Executive Officer

COCP · Cocrystal Pharma, Inc.

Effective: 2026-06-03
Successor: James Sapirstein
Filed: June 9, 2026, 7:00 AM ET

Mr. Sapirstein replaces Sam Lee and James Martin, who served as the Company’s Co-Chief Executive Officers.

Appointed

James Sapirstein

Chief Executive Officer

COCP · Cocrystal Pharma, Inc.

Effective: 2026-06-03
Filed: June 9, 2026, 7:00 AM ET

the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed James Sapirstein as the Chief Executive Officer of the Company, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.93

James Martin departed as Co-Chief Executive Officer at Cocrystal Pharma, Inc..

Action: replaced
Role: Co-Chief Executive Officer

Exact text from the filing

Mr. Sapirstein replaces Sam Lee and James Martin, who served as the Company’s Co-Chief Executive Officers.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.93

Sam Lee departed as Co-Chief Executive Officer at Cocrystal Pharma, Inc..

Action: replaced
Role: Co-Chief Executive Officer

Exact text from the filing

Mr. Sapirstein replaces Sam Lee and James Martin, who served as the Company’s Co-Chief Executive Officers.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James Sapirstein was appointed as Chief Executive Officer at Cocrystal Pharma, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed James Sapirstein as the Chief Executive Officer of the Company, effective immediately

View on SEC.gov

Cocrystal Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-027837

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.